Immix Biopharma (IMMX) Current Leases (2024 - 2026)

Quarterly results put Current Leases at $125392.0 for Q1 2026, up 84.9% from a year ago — trailing twelve months through Mar 2026 was $125392.0 (up 84.9% YoY), and the annual figure for FY2025 was $139339.0, up 113.65%.

Immix Biopharma has reported Current Leases over the past 3 years, most recently at $125392.0 for Q1 2026.

  • Current Leases reached $125392.0 in Q1 2026 per IMMX's latest filing, down from $139339.0 in the prior quarter.
  • Across five years, Current Leases topped out at $141282.0 in Q3 2025 and bottomed at $34284.0 in Q1 2024.
  • Median Current Leases over the past 3 years was $67817.0 (2025), compared with a mean of $83874.9.
  • Peak annual rise in Current Leases hit 125.28% in 2025, while the deepest fall reached 45.72% in 2025.
  • Over 3 years, Current Leases stood at $65219.0 in 2024, then soared by 113.65% to $139339.0 in 2025, then dropped by 10.01% to $125392.0 in 2026.
  • Business Quant data shows Current Leases for IMMX at $125392.0 in Q1 2026, $139339.0 in Q4 2025, and $141282.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Current Leases (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - 83,991.00
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn 7.40 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn -
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 720.00 Mn
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 45.66 Mn
10 Immix Biopharma 476.17 Mn 476.17 Mn - 125,392.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 125,392.00
Dec 31, 2025 139,339.00
Sep 30, 2025 141,282.00
Jun 30, 2025 70,467.00
Mar 31, 2025 67,817.00
Dec 31, 2024 65,219.00
Sep 30, 2024 62,715.00
Jun 30, 2024 48,359.00
Mar 31, 2024 34,284.00